Navigation Links
Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
Date:7/1/2008

riteria) was achieved with the outpatient administration of Dacogen, confirming previously reported response rates in the outpatient setting. The safety profile of this dosing regimen was consistent with what has been previously reported.

Eisai is committed to a clinical development program to optimize the utility of Dacogen for all patients with MDS. Recent studies of hypomethylating agents have suggested that treatment of patients should continue for as long as they receive clinical benefit or until their disease progresses. To advance the understanding of optimal treatment for MDS and related conditions, there are currently more than 30 ongoing trials with Dacogen either as a single agent or in combination with other therapies, including a Phase III survival study in older patients with acute myelogenous leukemia (AML).

Study Design

EORTC-06011: This Phase III open-label, randomized, multi-center, controlled trial evaluated overall survival of patients receiving Dacogen plus BSC versus BSC only. The study involved 233 elderly patients, greater than or equal to 60 years of age, with predominantly high-risk or Intermediate-2 type MDS.

Patients included in the trial had primary or secondary MDS with or without previous therapy with growth factors, immunosuppressive agents or hydroxyurea. In order to participate in the study, patients had to have bone marrow blast counts between 11 and 30 percent. Patients with blast counts below 10 percent were required to have had poor-risk cytogenetics in order to be eligible for randomization.

DACO-020: This is a multi-center, open-label, single arm Phase II study of Dacogen in 99 patients with de novo or secondary MDS. Dacogen was administered daily for five days repeated every four weeks. Patients were greater than or equal to 18 years of age with MDS (de novo or secondary) of any FAB subtype and with an International Prognostic Scoring System score of greater than or equal to 0.5. In order to
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting
2. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
3. New Data Demonstrates 5-FU Personalized Chemotherapy Management (PCM(R)) Assay Provides Similar Performance to More Complicated Liquid Chromatography-Mass Spectrometry (LC-MS/MS)
4. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
5. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
6. Clinical Proof of Concept for TGF-beta 2-Inhibitor AP 12009 in Phase Iib EMEA provides Guidance on Phase III Design and Approval Requirements
7. CNS Response, Inc. Provides Review of Poster Session Delivered at the American Psychiatric Association 161st Annual Meeting
8. Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohns Disease
9. Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients
10. Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone
11. New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 UBM Medica US announces that  ... to help oncologists and other clinicians gain a better ... of targeted therapies and immunotherapies, discusses some of the ... Every September, Blood Cancer Awareness Month ... about blood cancers—helping to increase survival rates and improve ...
(Date:9/19/2014)... 2014 According to market ... Mobile, Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, ... Rotary) & Geography - Global Trends & Forecast ... the lyophilization market on the basis of various ... of the market size of each of these ...
(Date:9/19/2014)... SAN DIEGO , Sept. 19, 2014 /PRNewswire/ ... industry leader in bioactive lipid-targeted therapeutics, announced today ... sell 3,605,042 registered shares of common stock and ... The combined purchase price for one registered share ... purchase one unregistered share of common stock will ...
Breaking Medicine Technology:OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3
... N.J., April 28, 2011 Savient Pharmaceuticals, Inc. (Nasdaq: ... presented at the European League Against Rheumatism (EULAR) 2011 Annual ... 28 in London, United Kingdom, and will feature the abstracts ... The first scheduled oral presentation and the poster session will ...
... April 28, 2011 Pharmasset, Inc. (Nasdaq: VRUS ... Healthcare Conference being held May 2 to 4, 2011 at ... America Merrill Lynch Healthcare Conference being held May 10 to ... Schaefer Price, Pharmasset,s President and Chief Executive Officer, will provide ...
Cached Medicine Technology:Savient Pharmaceuticals to Present Multiple Abstracts at The European League Against Rheumatism (EULAR) 2011 Annual Congress 2Pharmasset to Present at Two Upcoming Investor Conferences 2Pharmasset to Present at Two Upcoming Investor Conferences 3
(Date:9/19/2014)... NY (PRWEB) September 19, 2014 The ... the five years to 2014. Industry operators were able ... during the period, as well as establish distribution contracts ... due in large part to its novelty; energy drinks ... in that time, industry operators have been able to ...
(Date:9/19/2014)... 2013 NEXT Award-winning technology consultancy ... for the 2014 NEXT Awards in the Technology ... has been selected as the sole female finalist ... Chamber of Commerce and the Nashville Entrepreneur Center ... accomplishments of companies and individual entrepreneurs in five ...
(Date:9/19/2014)... San Jose, California (PRWEB) September 19, 2014 ... – Buoyed by technological advancements, surgical techniques, and ... become the preferred treatment for several chronic diseases ... liver. Advancements in organ and tissue transplantation have ... patients. Organ transplant today represents a ...
(Date:9/19/2014)... researchers at the University of Utah School of Medicine ... of mitochondria in debilitating and fatal motor neuron diseases ... such illnesses. , Researchers led ... when healthy, functioning mitochondria was prevented from moving along ... neurons mice developed symptoms of neurodegenerative diseases. In ...
(Date:9/19/2014)... grow well in infertile land, and bear many beans ... is because most legumes have a symbiotic relationship with ... air and then supply the host plant with ammonia ... organs called nodules in their roots. However, if too ... the growth of the plants, because the energy cost ...
Breaking Medicine News(10 mins):Health News:Relaxation Drink Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Relaxation Drink Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Virsys12 and Founder Tammy Hawes Each Named 2014 NEXT Awards Finalists 2Health News:Virsys12 and Founder Tammy Hawes Each Named 2014 NEXT Awards Finalists 3Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Growing Number of Terminally Ill Patients Drive the Global Organ and Tissue Transplantation Market, According to New Report by Global Industry Analysts, Inc. 4Health News:Mouse model sheds light on role of mitochondria in neurodegenerative diseases 2Health News:Mouse model sheds light on role of mitochondria in neurodegenerative diseases 3Health News:Long-distance communication from leaves to roots 2
... June 29 Medicsight PLC, a subsidiary of MGT Capital ... industry leader in the development of Computer-Aided Detection (CAD) and ... of disease, is pleased to announce the launch of its ... benefits of Medicsight,s ColonCAD software truly accessible to all radiologists ...
... , LONDON, June 29 The Healthcare Group at ... Quarterly Analyst Briefing Presentation on the European Hospital Information Systems ... at 2 p.m. GMT. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ... some kind of information system in place, only a few ...
... Clarient, Inc. (Nasdaq: ... services resource for pathologists, oncologists and the pharmaceutical industry, today announced ... Index when Russell Investments reconstitutes its comprehensive set of U.S. and ... of additions posted June 12 on www.russell.com . ...
... ... your pet healthy and happy and is more likely to avoid serious and costly health problems ... ... health care can prevent expensive vet bills in the future, pet owners are reminded, as everyone continues ...
... Florida,s First Certified Urgent ... County Florida has become the first in the State to receive formal recognition as a Certified ... ... Care Medical Centers of Palm Beach County Florida has become the first in the State to ...
... ... to access critical health data stored in electronic health records (EHRs). The company has just ... , ... 29, 2009 -- Orion Health , a market leader in providing clinical workflow and ...
Cached Medicine News:Health News:Medicsight Launches ColonCAD(TM) Online CTC Platform 2Health News:Medicsight Launches ColonCAD(TM) Online CTC Platform 3Health News:Hospital Information Systems (HIS) Markets in Europe: Frost & Sullivan Reveals the Cost, Crunch and the Care Value 2Health News:Clarient Set to Join Russell 3000 Index 2Health News:Clarient Set to Join Russell 3000 Index 3Health News:Clarient Set to Join Russell 3000 Index 4Health News:Proactive Pet Care Essential in Low Cash Times, Says NOAH 2Health News:Proactive Pet Care Essential in Low Cash Times, Says NOAH 3Health News:MD Now Urgent Care Centers: First in Florida to Receive UCAOA Certification in Urgent Care 2Health News:MD Now Urgent Care Centers: First in Florida to Receive UCAOA Certification in Urgent Care 3Health News:Expanding into New Markets with Customer-Focused Solutions, Orion Health Sees Strong Growth 2Health News:Expanding into New Markets with Customer-Focused Solutions, Orion Health Sees Strong Growth 3
... The Driver Stent design, ... surpasses the limitations of stainless ... makes possible thinner struts, for ... support. The Driver Coronary Stent ...
The complete performance package. Precision handling. Stable platform for device delivery. Enhanced backup support. Unique braid technology. Improved curve retention. Smooth PTFE liner....
The soft tip sheath design for smooth delivery and retrieval of Constellation advanced mapping basket catheters....
Fast-Cath, Maximum, Maximum Xtra, and Maximum ACT introducers represent the largest line of standard and specialty hemostasis introducers in the world....
Medicine Products: